Your browser doesn't support javascript.
loading
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations.
Meric-Bernstam, Funda; Lloyd, Michael W; Koc, Soner; Evrard, Yvonne A; McShane, Lisa M; Lewis, Michael T; Evans, Kurt W; Li, Dali; Rubinstein, Lawrence; Welm, Alana; Dean, Dennis A; Srivastava, Anuj; Grover, Jeffrey W; Ha, Min J; Chen, Huiqin; Huang, Xuelin; Varadarajan, Kaushik; Wang, Jing; Roth, Jack A; Welm, Bryan; Govinden, Ramaswamy; Ding, Li; Kaochar, Salma; Mitsiades, Nicholas; Carvajal-Carmona, Luis; Herylyn, Meenhard; Davies, Michael A; Shapiro, Geoffrey I; Fields, Ryan; Trevino, Jose G; Harrell, Joshua C; Doroshow, James H; Chuang, Jeffrey H; Moscow, Jeffrey A.
Afiliação
  • Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lloyd MW; The Jackson Laboratory, Bar Harbor, Maine.
  • Koc S; Seven Bridges Genomics, Charlestown, Massachusetts.
  • Evrard YA; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
  • McShane LM; Biometric Research Program, DCTD, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Lewis MT; Departments of Molecular and Cellular Biology and Radiology, Lester and Sue Smith Breast Center, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
  • Evans KW; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Li D; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Rubinstein L; Biometric Research Program, DCTD, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Welm A; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  • Dean DA; Seven Bridges Genomics, Charlestown, Massachusetts.
  • Srivastava A; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.
  • Grover JW; Seven Bridges Genomics, Charlestown, Massachusetts.
  • Ha MJ; Department of Biostatistics, Graduate School of Public Health, Yonsei University, Seoul, Republic of Korea.
  • Chen H; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Huang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Varadarajan K; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wang J; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Roth JA; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Welm B; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  • Govinden R; Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
  • Ding L; Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
  • Kaochar S; Department of Medicine, Baylor College of Medicine, Houston, Texas.
  • Mitsiades N; Department of Molecular Cellular Biology, Baylor College of Medicine, Houston, Texas.
  • Carvajal-Carmona L; Department of Biochemistry and Molecular Medicine, University of California, Davis, California.
  • Herylyn M; The Wistar Institute, Philadelphia, Pennsylvania.
  • Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Fields R; Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.
  • Trevino JG; Department of Surgery, Virginia Commonwealth University, Richmond, Virginia.
  • Harrell JC; Department of Pathology, Virginia Commonwealth University, Richmond, Virginia.
  • Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Chuang JH; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.
  • Moscow JA; Investigational Drug Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Mol Cancer Ther ; 23(7): 924-938, 2024 Jul 02.
Article em En | MEDLINE | ID: mdl-38641411
ABSTRACT
Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating the comparison of different studies and determination of whether a PDX experiment has produced evidence needed to consider a new therapy promising. We present consensus recommendations for assessment of PDX growth and antitumor activity, providing public access to a suite of tools for in vivo growth analyses. We expect that harmonizing PDX study design and analysis and assessing a suite of analytical tools will enhance information exchange and facilitate identification of promising novel therapies and biomarkers for guiding cancer therapy.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ensaios Antitumorais Modelo de Xenoenxerto / Neoplasias Limite: Animals / Humans País como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ensaios Antitumorais Modelo de Xenoenxerto / Neoplasias Limite: Animals / Humans País como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article